Charles Sawyers, Chair, Human Oncology and Pathogenesis Program
Board members Sandy Markowitz, Bill Kaelin, Ederlinda Paraiso (HOPP Administrator), and Todd Golub
Board members Sandford Markowitz, Bill Kaelin, and Todd Golub
Board member Lynda Chin
Board member Steven Leach
Human Oncology and Pathogensis faculty members Marc Ladanyi, Christopher Park, James Fagin, and Ross Levine
Human Oncology and Pathogensis faculty members Adriana Heguy and David Solit
Board members and Human Oncology and Pathogensis faculty members
Board members James Downing and Kevin Shannon
Board members Kevin Shannon and Sandford Markowitz with Human Oncology and Pathogensis faculty member Neal Rosen
Board members Steven Leach, Sandy Markowitz, and Bill Kaelin
The Human Oncology and Pathogenesis Program (HOPP) was created in late 2005 under the leadership of Charles Sawyers, MD. The Program is working to assemble a group of outstanding physician-scientists with laboratory-based training in cancer research; build infrastructure for conducting clinical trials that incorporate powerful molecular profiling technologies; and provide a world-class training environment for graduate students, postdoctoral fellows, clinical fellows, and junior faculty who are interested in translational research.
To maximize the resources and advantages of this unique program, Dr. Sawyers sought advice from a panel of world-renowned research experts — known as the HOPP External Advisory Board (EAB). The EAB has provided invaluable input on the strategic planning for HOPP. EAB members help identify outstanding young recruits, provide information on the latest technology and research trends, and evaluate the research portfolios of HOPP faculty members and our core facility leader.
External Advisory Board Members
Lynda Chin, MD, joined MD Anderson in September 2011, as chair of Genomic Medicine and scientific director of the Institute for Applied Cancer Sciences.
Kathleen R. Cho, MD, is the Peter A. Ward Professor of Pathology and Professor of Internal Medicine in the University of Michigan Medical School, and serves as Section Head of gynecological pathology at the University of Michigan Health System. Dr. Cho’s research group is working to identify and characterize the genetic alterations that underlie the development and progression of cervical and ovarian cancers. They develop murine models of gynecological cancers based on the molecular defects present in their human tumor counterparts, and use them as preclinical tools for testing novel therapeutic strategies that target the signaling pathways deregulated by specific genetic alterations.
James R. Downing, MD, holds the titles of Scientific Director, Associate Director of Basic Research, Co-Leader in the Hematological Malignancies Program and Director of the Molecular Pathology Laboratory at St. Jude Children’s Research Hospital. His research interest are focused on elucidating the molecular mechanisms of leukemogenesis.
, is Director of the Broad Institute’s Cancer Program, a Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, an investigator at Howard Hughes Medical Institute, and professor of pediatrics at Harvard Medical School. Dr. Golub is a world leader in applying genomic tools to the classification and study of cancers. His research uses knowledge gained from the human genome to understand the biological and clinical challenges facing cancer medicine. He has made fundamental discoveries related to the molecular basis of childhood leukemia, and pioneered the use of genomic approaches, particularly DNA microarrays, to cancer biology. Todd Golub, MD
William Kaelin, MD, is a professor of medicine at Dana-Farber Cancer Institute and at Brigham and Women’s Hospital, Harvard Medical School; Senior Physician at Brigham and Women’s Hospital; and Associate Director, Basic Science, of the Dana-Farber/Harvard Cancer Center. He is also an HHMI investigator. His research focuses on understanding why mutations affecting tumor-suppressor genes cause cancer. His long-term goal is to lay the foundation for the development of new anticancer therapies that are based on the biochemical functions of specific tumor-suppressor proteins.
Sandy Markowitz, MD, PhD, is a Howard Hughes Medical Institute investigator and the Francis Wragg Ingalls Professor of Cancer Genetics in the Department of Medicine (Hematology-Oncology) and the Ireland Cancer Center, with co-appointment in the Department of Molecular Biology, at Case Western Reserve University School of Medicine. He is also an attending physician at University Hospitals of Cleveland. His laboratory focuses on molecular abnormalities in colon cancer, and is studying colon cancer suppressor genes and oncogenes, the functions of positive and negative regulatory growth factors, and the role of genomic instability in inherited and sporadic colon cancers.
Kevin Shannon, MD, is an Auerback Distinguished Professor in Molecular Oncology, Director of the Medical Scientist Training Program, and Interim Chair of the Department of Pediatrics at the University of California, San Francisco. He is also a pediatric hematologist and oncologist at UCSF Medical Center. His lab investigates the causes of leukemia, mechanisms of hematopoietic growth control and leukemogenesis, treatment response and resistance, and novel experimental strategies. These studies are conducted in human cells and mouse models.